Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
Eleanor Williams(University of Oxford), Alex N. Bullock(Genomics (United Kingdom))
Cited by 10
Related Papers
Thermodynamic stability of wild-type and mutant p53 core domain
|Proceedings of the National Academy of Sciences|1997|417
A New Class of Small Molecule Inhibitor of BMP Signaling
|PLoS ONE|2013|239
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
|JCI Insight|2021|69
LIM Domain Kinase 1 (LIMK1), Human Kinase Domain; A Target Enabling Package
|Oxford University Research Archive (ORA) (University of Oxford)|2018|0